Investor Centre
Our broad clinical and preclinical pipeline in oncology and behavioural brain disorders focuses on indications including glioblastoma, neurodevelopmental disorders, addiction, anxiety, fatigue and narcolepsy.
0.25 GBX
Volume:
2,031,406
Market Capitalisation (m)
£5.37
TheraCryf plc Investor Presentation
Cavendish Research Note
12 - May - 2025Research Note by Cavendish following announcement of the CDMO/CRO selection to progress the Orexin-1 programme
TheraCryf plc Investor Webinar
03 - April - 2025Hosted by Turner Pope Investments, Dr Huw Jones (CEO) and Dr Alastair Smith (Non-executive Chair) present a webinar focused on the Company’s plans for Ox-1 and SFX-01.
Major Shareholders
| Current Shareholder | Number of shares | Percentage holding |
|---|---|---|
| Tracarta Limited | 422,727,272 | 19.67% |
| First Equity Limited | 179,000,000 | 8.33% |
| T and I Limited | 160,000,000 | 7.45% |
| Spreadex Limited | 83,050,001 | 3.86% |
| Oberon Investments Limited | 80,475,000 | 3.74% |
| A Leach | 80,000,000 | 3.72% |
| S Gibeon | 71,400,000 | 3.32% |
| J. R. Kight | 56,100,000 | 2.61% |
| Rathbones Investment Management Ltd | 24,835,704 | 1.16% |
| Octopus Investments | 21,875,000 | 1.02% |
| Vulpes Investment Management Pte Ltd | 20,554,191 | 0.96% |
| Seneca Partners Limited | 16,301,456 | 0.76% |
The number of ordinary shares in issue is 2,148,963,739 all of which are in public hands. The Company does not hold any shares in Treasury.
